RapidAI — SEC Form D Filing

RapidAI filed an SEC Form D on August 14, 2026, reporting $75.00M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
August 14, 2026
Amount reported
$75.00M
Industry
Healthcare Technology
Website
https://www.rapidai.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Healthcare systems struggle with managing disconnected AI tools across departments and hospitals, leading to unsustainable processes and unreliable clinical AI performance that can affect patient care. Additionally, critical conditions like pulmonary embolism (PE) suffer from delayed care due to uncoordinated workflows, resulting in a low percentage of patients receiving advanced therapies.

Solution

RapidAI provides an enterprise platform that utilizes deep clinical AI and hybrid infrastructure to enhance clinical decision-making, streamline workflows, and ensure reliable, secure, and integrated AI operations across health systems for various conditions including neurovascular, cardiac, and vascular diseases. This platform includes tools for rapid identification, quantification, and communication of critical findings, such as for stroke, aortic conditions, and pulmonary embolism.

Why now

Advances in AI, particularly deep learning and computer vision, now allow for rapid and accurate analysis of complex medical imaging data, enabling real-time decision support that was previously impossible.

Verdict

Investors said yes to an enterprise platform promising to manage disparate AI tools and streamline critical care workflows, leveraging recent advances in deep learning for medical imaging. This cleared because the narrative bet on a clear path to revenue through immediate clinical utility for life-threatening conditions, not because it promised a disruptive shift in healthcare economics. They were implicitly betting on the company's ability to navigate complex hospital IT environments and integrate fragmented AI solutions, accepting that widespread AI adoption in healthcare would be a gradual, condition-specific rollout rather than a sudden transformation.

Source: SEC EDGAR Form D filing